Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 12
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Last day of trading in warrants series TO 12 in Alligator Bioscience is 15 May 2025
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience to attend ASCO 2025 Annual Meeting
Lund, Sweden, 12 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) is pleased to announce that data from its OPTIMIZE-1 clinic ...
Alligator Bioscience announces that 85% of the warrant programme TO 12 has been secured and that the outstanding loan has been renegotiated
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience updates dividend policy
Alligator Bioscience AB (publ) today announces an update to its dividend policy following the constitution of Alligator’s new Board of ...
Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Change in number of shares and votes in Alligator Bioscience AB
During April 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has decreased as a result ...
Exercise price determined for the exercise of warrants series TO 12 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience AB reports financial results for Q1 2025 and provides a business update
24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab—three times higher than chemotherapy alone FDA alignment secure ...